News and Events, Recent News

BriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer

Berkeley, CA and Vancouver, BC – July 19, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, provided a clinical update regarding its US-based open-label Phase I/IIa clinical trial evaluating the safety and efficacy of BriaVax™, a genetically engineered whole-cell vaccine derived from a human breast […]

News and Events, Recent News

BriaCell Completes Manufacturing of New Batch of BriaVax™

Berkeley, CA and Vancouver, BC – July 5, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, announced today that it has successfully manufactured a new batch of its BriaVax™ vaccine, and that this new batch has passed all release testing in compliance with recent guidelines […]